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Microbial natural products: molecular blueprints for antitumor
drugs
Lesley-Ann Giddings • David J. Newman

Abstract Microbes from two of the three domains of life,
the Prokarya, and Eukarya, continue to serve as rich
sources of structurally complex chemical scaffolds that
have proven to be essential for the development of anticancer therapeutics. This review describes only a handful
of exemplary natural products and their derivatives as well
as those that have served as elegant blueprints for the
development of novel synthetic structures that are either
currently in use or in clinical or preclinical trials together
with some of their earlier analogs in some cases whose
failure to proceed aided in the derivation of later compounds. In every case, a microbe has been either identified
as the producer of secondary metabolites or speculated to
be involved in the production via symbiotic associations.
Finally, rapidly evolving next-generation sequencing
technologies have led to the increasing availability of
microbial genomes. Relevant examples of genome mining
and genetic manipulation are discussed, demonstrating that
we have only barely scratched the surface with regards to
harnessing the potential of microbes as sources of new
pharmaceutical leads/agents or biological probes.
Keywords Microbial natural product  Microbial
genome  Cancer drugs  Clinical trial
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Introduction
Although Man has used natural product extracts to treat
diseases for thousands of years, the era of modern chemotherapy began in the 1940s with the use of nitrogen
mustards, hormones, and folic acid antagonists. During
World War II (1939–1945), the demand for penicillin, in
addition to other new antibiotics, led to major pharmaceutical companies forming large research programs centered on natural products discovery. These programs aimed to
identify new secondary metabolites with a variety of novel
biological activities, including anticancer activities. During
this time, academic laboratories and government agencies,
such as the National Cancer Institute, also assisted pharmaceutical companies and spearheaded research programs that
led to the discovery of many natural products, which are either
currently used in the clinic or in active development.
The fields of microbiology, chemistry, and pharmacology have been instrumental in the search for novel agents
that treat or ameliorate cancer. Throughout the last
70 years, natural products from the Prokarya predominately the actinomycetes, and Eukarya or their corresponding derivatives have played extremely important
roles in drug discovery. Notably, microbial secondary
metabolites, especially now from the marine environment,
are the major source of drugs used for direct treatment as
well as scaffolds upon which chemists can selectively
modify to modulate activities against tumor cell growth. As
a result of these efforts, there are currently 189 small
molecule agents (excluding biologicals or vaccines, but
including warheads on monoclonal antibodies) available
worldwide that can be categorized as the following : N (29;
16 %), NB (1, 0.5 %), ND (59; 31 %), S (44; 23 %), S/NM
(19; 10 %), S* (20; 11 %), and S*/NM (17; 9 %) [150–
152]. The definitions are given as a footnote in Table 1.

123

Downloaded from https://academic.oup.com/jimb/article/40/11/1181/5994885 by guest on 21 February 2022

Received: 2 April 2013 / Accepted: 7 August 2013 / Published online: 3 September 2013
Ó Society for Industrial Microbiology and Biotechnology (Outside the USA) 2013

1182

Terrestrial sources
During the 1950s to 1990s, pharmaceutical companies led
an exhaustive search for new drugs produced by microbes
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Table 1 All world-wide approved (1930s to 31DEC2012) small
molecule antitumor drugs with identification of those either directly
produced by microbes or are derivatives of microbial secondary
metabolites
Generic name

Year
introduced

Source

Testosterone

Pre-1970

N

Streptozocin

Pre-1977

N

Yes

Leucovorin

1950

N

Yes

Carzinophilin

1954

N

Yes

Sarkomycin

1954

N

Yes

Mitomycin C

1956

N

Yes

Chromomycin A3

1961

N

Yes

Mithramycin

1961

N

Yes

Vincristine

1963

N

Actinomycin D
Vinblastine

1964
1965

N
N

Yes

Bleomycin

1966

N

Yes

Doxorubicin

1966

N

Yes

Daunomycin

1967

N

Yes

Asparaginase

1969

N

Yes

Neocarzinostatin

1976

N

Yes

Aclarubicin

1981

N

Yes

Peplomycin

1981

N

Yes

Masoprocol

1992

N

Pentostatin

1992

N

Paclitaxel

1993

N

Angiotensin II

1994

N

Arglabin

1999

N

Microbe

Yes

Paclitaxel nanoparticlesa

2005

N

Trabectedin
Paclitaxel nanoparticlesa

2007
2007

N
N

Yes

Romidepsin

2010

N

Yes

3-Angeloylingenol

2012

N

Homoharringtonine

2012

N

Solamargines

1989

NB

Ethinyl estradiol

Pre-1970

ND

Fluoxymesterone

Pre-1970

ND

Hydroxyprogesterone

Pre-1970

ND

Prednisone

Pre-1970

ND

Fosfestrol

Pre-1977

ND

Norethindrone acetate

Pre-1977

ND

Prednisolone

Pre-1977

ND

Methylprednisolone

1955

ND

Dexamethasone

1958

ND

Medroxyprogesterone acetate

1958

ND

Triamcinolone
Nandrolone phenylpropionate

1958
1959

ND
ND

Dromostanolone

1961

ND

Teniposide

1967

ND

Testolactone

1969

ND
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Table 1 lists the 189 approved (by the FDA or equivalent) small molecule drugs, of which 89 (47 %) fall under
the N, NB or ND classifications (see footnote in Table 1 for
definitions) and to this number we have added Ara-C,
which has also been reported from microbes, thus
increasing the denominator to 90. Of these 90 natural
product-related approved antitumor drugs, 30 (33 %) are
either directly produced by microbes or are derivatives of
microbial secondary metabolites. Of the remaining drugs
on the list, some are based on pharmacophores derived
from microbial natural products (e.g., vorinostat/mitoxantrone HCl), and nucleoside derivatives, which, with the
exception of floxuridine (5-FU) and mercaptopurine, can
be traced back to Bergmann’s reports in the 1950s on
sponge-derived arabinoside nucleosides [15–17], and thus
the recognition that one can modify the sugar while still
maintaining biological activity.
Since the 1990s, large pharmaceutical companies have
deemphasized natural product discovery due to the advent
of high-throughput screening programs based on molecular
targets and combinatorial chemistry. These research programs were projected to speed up the drug development
process and reduce costs. Ironically, instead of creating
large libraries, combinatorial chemistry is now used to build
small, focused collections that resemble the core scaffolds
of natural products. In addition, even with this shift in focus,
there is still a shortage of lead compounds entering clinical
trials. Approximately 50 % of all small molecules that were
approved by the FDA between 2000 and 2006 were not the
new chemical entities derived from combinatorial chemistry but rather based upon natural products [150]. With
increasingly available genomic sequences and the recent
advances in metagenomic analyses, we now have more
access to the sequences of biosynthetic gene clusters,
especially those that are silent, which often may comprise a
significant fraction of the microbial genome [181]. This
review describes the brief history of nominally terrestrial
microbial-sourced antitumor agents (secondary metabolites
and derivatives based upon either their basic structure and/
or pharmacophores), new agents based upon these scaffolds, and marine-sourced materials that are either presumptively by structural analogy or directly from microbes
due to their chemical novelty and potency. Lastly, the
influence of microbial genomic information on the discovery of new secondary metabolites as well as the potential
sources of well-known plant-sourced anticancer agents and
their implications will be discussed.
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Table 1 continued
Generic name

Table 1 continued
Year
introduced

Source

Microbe

Generic name

Year
introduced

Source

Megestrol acetate

1971

ND

Levamisole

Pre-1981

S

Calusterone

1973

ND

Nimustine hydrochloride

Pre-1981

S

Methyltestosterone

1974

ND

Triethylenemelamine

Pre-1981

S

Mitobronitol

1979

ND

Busulfan

1954

S

Vindesine

1979

ND

Chlorambucil

1956

S

Estramustine

1980

ND

Cyclophosphamide

1957

S

Etoposide

1980

ND

Mechlorethamine

1958

S

1983

ND

Thiotepa

1959

S

Epirubicin hydrochloride
Triptorelin

1984
1986

ND
ND

Yes

Melphalan
Pipobroman

1961
1966

S
S

Pirarubicin

1988

ND

Yes

Hydroxyurea

1968

S

Vinorelbine

1989

ND

Idarubicin hydrochloride

1990

ND

Cladribine

1993

ND

Cytarabine ocfosfate

1993

ND

Formestane

1993

Miltefosine
Irinotecan hydrochloride

Procarbazine

1969

S

Mitotane

1970

S

Dacarbazine

1975

S

Ifosfamide

1976

S

ND

Lomustine (CCNU)

1976

S

1993

ND

Carmustine (BCNU)

1977

S

1994

ND

cis-Diamminedichloroplatinum

1979

S

Yes
Yes

Zinostatin stimalamer

1994

ND

Hexamethylmelamine

1979

S

Docetaxel

1995

ND

Aminoglutethimide

1981

S

Etoposide phosphate

1996

ND

Flutamide

1983

S

Topotecan hydrochloride

1996

ND

Carboplatin

1986

S

Alitretinoin

1999

ND

Amsacrine

1987

S

Exemestane
Valrubicin

1999
1999

ND
ND

Yes

Lonidamine
Nilutamide

1987
1987

S
S

Gemtuzumab ozogamicin

2000

ND

Yes

Ranimustine

1987

S

Amrubicin hydrochloride

2002

ND

Yes

Fotemustine

1989

S

Fulvestrant

2002

ND

Bisantrene hydrochloride

1990

S

Belotecan hydrochloride

2004

ND

Porfimer sodium

1993

S

Hexyl aminolevulinate

2004

ND

Sobuzoxane

1994

S

Talaporfin sodium

2004

ND

Nedaplatin

1995

S

Vapreotide acetate

2004

ND

Oxaliplatin

1996

S

Temsirolimus

2007

ND

Yes

Lobaplatin

1998

S

Ixabepilone

2007

ND

Yes

Heptaplatin/SK-2053R

1999

S

Pralatrexate

2009

ND

Arsenic trioxide

2000

S

Mifamurtide

2010

ND

Zoledronic acid

2000

S

Vinflunine

2010

ND

Sorafenib

2005

S

Yes

Cabazitaxel

2010

ND

Plerixafor hydrochloride

2009

S

Eribulin
Abiraterone acetate

2010
2011

ND
ND

Miriplatin hydrate
Vismodegib

2010
2012

S
S

Brentuximab vedotin

2011

ND

Nafoxidine

Pre-1977

S/NM

BF-200 ALA

2012

ND

Tamoxifen

1973

S/NM

Carfilzomib

2012

ND

Camostat mesylate

1985

S/NM

Pasireotide

2012

ND

Toremifene

1989

S/NM

Diethylstilbestrol

Pre-1970

S

Anastrozole

1995

S/NM

Razoxane

Pre-1977

S

Bicalutamide

1995

S/NM

Semustine (MCCNU)

Pre-1977

S

Fadrozole hydrochloride

1995

S/NM

Chlorotrianisene

Pre-1981

S

Letrozole

1996

S/NM

Yes
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Elliptinium acetate

Microbe
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Table 1 continued
Generic name

Table 1 continued
Year
introduced

Source

Microbe

Generic name

Year
introduced

Source

Microbe

Imatinib mesylate

2001

S/NM

Regorafenib

2012

S*/NM

Gefitinib

2002

S/NM

Radotinib

2012

S*/NM

Temoporfin

2002

S/NM

Bortezomib

2003

S/NM

Erlotinib hydrochloride

2004

S/NM

N natural product, NB natural product botanical (a defined mixture of
compounds), ND derived from a natural product; usually a semisynthetic modification, S totally synthetic drug, S* made by total
synthesis; pharmacophore from a natural product, NM natural product
mimic (sub-category) [150, 152]

Sunitinib malate

2006

S/NM

Dasatinib

2006

S/NM

Lapatinib ditosylate

2007

S/NM

Nilotinib hydrochloride
Pazopanib

2007
2009

S/NM
S/NM

Enzalutamide

2012

S/NM

Azacytidine

Pre-1977

S*

Mercaptopurine

1953

S*

Methotrexate

1954

S*

Fluorouracil

1962

S*

Thioguanine

1966

S*

Uracil mustard

1966

S*

Cytosine arabinoside

1969

S*

Floxuridine

1971

S*

Ftorafur

1972

S*

Carmofur

1981

S*

Enocitabine

1983

S*

Mitoxantrone hydrochloride

1984

S*

Doxifluridine
Fludarabine phosphate

1987
1991

S*
S*

Actinomycins, anthracyclines, and bleomycins
Waksman’s discovery of the actinomycins in various species of soil Streptomyces [226] in 1940 led to many firsts in
1952, namely actinomycin C was the first crystalline
antibiotic as well as the first antibiotic to demonstrate
in vitro antitumor activity [76]. That same year, Schulte
reported the first clinical studies with these agents [183]. In
1963, actinomycin D (Act D, 1; Fig. 1) was approved for
the treatment of highly malignant tumors. However, its use
has been limited by its extreme cytotoxicity, thus doses of
Act D are carefully calculated for each patient to primarily
treat rhabdomyosarcoma and Wilms’ tumor in children or
for use in combination regimens.
Act D consists of a planar 2-aminophenoxazin-3-one
chromophore and two large cyclic pentapeptide lactones.
This agent is a DNA intercalator that competes for transcription factor DNA binding sequences, thereby inhibiting
RNA and protein synthesis [70]. The antitumor activity of
Act D has been reported to be attenuated by polyamines,
such as spermine, but if a polyamine inhibitor such as
methyl glyoxal-bis(guanylhydrazone) (MGBG) was added
to the Act D treatment, then a synergistic effect was seen in
a cell proliferation assay. Thus it is possible that such a
combination can be exploited to enhance the anticancer

1995

S*

Capecitabine

1998

S*

Azacytidine

2004

S*

Clofarabine

2005

S*

Nelarabine

2006

S*

Decitabine

2006

S*

Pixantrone maleate

2012

S*

Raltitrexed

1996

S*/NM

Temozolomide

1999

S*/NM

Bexarotene

2000

S*/NM

Abarelix

2004

S*/NM

Pemetrexed disodium

2004

S*/NM

Tamibarotene

2005

S*/NM

Vorinostat
Degarelix

2006
2009

S*/NM
S*/NM

Vandetanib

2011

S*/NM

Crizotinib

2011

S*/NM

Vemurafenib

2011

S*/NM

Ruxolitinib phosphate

2011

S*/NM

Axitinib

2012

S*/NM

Bosutinib

2012

S*/NM

Cabozantinib S-malate

2012

S*/NM

123

Yes

Quite different preparations

from a variety of terrestrial environments. Based on the
biological activities of the novel metabolites identified
from these microbes, the bacteria of the order Actinomycetales have undoubtedly produced some of the most utilized structures directly from nature and semisynthetic
modifications. These soil bacteria have been the leading
producers of medically useful drugs and have provided also
basic templates for synthetic modifications. Other rich
sources of secondary metabolites include fungi and myxobacteria. Here, we highlight some of the key secondary
metabolites isolated from terrestrial microbes that have
been approved as drugs or provided significant leads in the
drug discovery process.
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activity of the drug [228]. Several derivatives have been
identified in various soil Streptomyces [19] and developed
using precursor-directed biosynthesis and synthetic methods to modulate their cytotoxicity [134, 135]. In addition to
terrestrial sources, Act D has also been isolated from a
marine-derived strain (Streptomyces sp. MS449) from a
sediment sample collected from the South China Sea [32].
Anthracyclines

leukemia; and berubicin hydrochloride (Reata Pharmaceuticals Inc; NCT00538343; 14; Fig. 1), in which a benzyl ether is attached to the sugar moiety, completed Phase I
clinical trials (NCT00538343) but is no longer in Phase II
clinical trials for breast cancer patients with recurrent brain
metastases due to low enrollment. In addition, several
liposomal and PEGylated formulations are currently being
explored. The FDA approved the use of the liposomeencapsulated doxorubicin DoxilÒ in combination regimens
for the treatment of mainly recurrent ovarian cancer;
however, the side effects are similar to those of free
doxorubicin. As a result, other drug delivery systems,
such as monoclonal antibody (NCT01101594) and peptide
conjugates (NCT01698281), nanoparticles (NCT01
655693), liposomes (NCT01170650) [30], and carbohydrates [202], several of which are currently in Phase I–III
clinical trials, are now being explored for increased efficiency and direct uptake by cancer cells.
Bleomycins
Another series of extremely important molecules from the
Actinomycetales are the family of glycopeptide antibiotics
known as the bleomycins, particularly bleomycin A2 sulfate (15; Fig. 2). Bleomycins share a core structure but
differ based on the presence of various positively charged
functional groups and disaccharides. These molecules were
originally isolated from Streptomyces verticillus by
Umezawa’s group at the Institute of Microbial Chemistry
in Tokyo, and were developed as antitumor agents by
Bristol Myers. Bleomycins are currently used in the treatment of squamous cell carcinomas, germ cell tumors, and
select lymphomas. Their original mechanism of action was
elucidated by Hecht and coworkers who demonstrated that
a metal ion (Cu2? or Fe2?) is required to activate the
sequence-specific oxidative cleavage of the DNA [83, 196]
and RNA [84]. The early work in the synthesis, mechanism, and DNA–RNA interactions of bleomycins were
described by Hecht in a 2005 review [85] with an update in
2012 [86]. In 2006 a potential RNA target for bleomycins
was reported [205], and in 2008, strong DNA-binding
motifs for metal-free bleomycins (since the clinical relevance of zinc and iron-bound bleomycin is unknown) were
identified [5]. The therapeutic efficacy of bleomycin(s) is
limited due to its extreme pulmonary toxicity. A new
bleomycin antibiotic, NC-0604 (16; Fig. 2), was isolated
from the fermentation broth of Streptomyces verticillus var.
pingyangensis n. sp. and reported to exhibit stronger
cytotoxicity in a variety of human tumor cell lines compared to bleomycin [31]. Notably, NC-0604 has lower
pulmonary toxicity compared to other bleomycins and is
currently in preclinical trials. Alternative drug delivery
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Following the discovery of the actinomycins, a wide
variety of antibiotics, including the bleomycins, mitomycins, mithramycins, and anthracyclines, from terrestrial
microbial sources were tested for antitumor activity and
their core structures were subsequently developed for
clinical use. Two of the most useful anthracyclines are
daunorubicin (2; Fig. 1) and doxorubicin (adriamycin, 3;
Fig. 1) isolated from Streptomyces peucetius and various
related strains. The FDA approved the use of daunorubicin
and doxorubicin for cancer therapy in the 1960s. Daunorubicin is used in the treatment of acute lymphoblastic or
myeloblastic lymphoma, whereas doxorubicin, which terminates in a primary alcohol instead of a methyl group, is
used in the treatment of breast cancer, solid tumors in
children, soft tissue sarcomas, and aggressive lymphomas.
The major drawbacks to these compounds are their significant cardiotoxicity, which can lead to congestive heart
failure, the development of resistance by tumor cells, and
the fact that there is lifetime limit on the gross amounts
used for treatment. To circumvent these problems, thousands of analogs of anthracyclines have been structurally
modified or synthesized through semi- or total synthesis,
but only a few compounds have reached the stage of
clinical development and approval. These include the
anthracycline analogs epirubicin (4; Fig. 1), pirarubicin (5;
Fig. 1), idarubicin (6; Fig. 1), valrubicin (7; Fig. 1), amrubicin (8; Fig. 1), aclarubicin (9; Fig. 1), and a combination of anthracycline and anthracene dione structural
classes, mitoxantrone hydrochloride (10; Fig. 1) and pixantrone dimaleate (11; Fig. 1). A comprehensive review of
anthracyclines can be found in the two recent volumes
edited by Krohn [115, 116].
The following chemical modifications of the basic
doxorubicin skeleton are currently being investigated in
Phase I–II trials: sabarubicin hydrochloride (Menarini;
ClinicalTrials.gov identifiers: NCT00027781, NCT0000
3982, and NCT00003028; 12; Fig. 1), in which the major
structural modification is the addition of a sugar moiety,
completed Phase II clinical trials for the treatment of
prostate cancer; annamycin, a liposomal variant of doxorubicin (Callisto Pharmaceuticals Inc; NCT00271063; 13;
Fig. 1) is in Phase I/II clinical trials for the treatment of
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b Fig. 1 The chemical structures of actinomycin D and representative

methods, such as photochemical internalization, are also
currently being investigated in Phase II clinical trials to
improve the incorporation of bleomycins into endosomal
membranes for the treatment of recurrent squamous cell
carcinoma (NCT01606566).

anthracyclines. (1) Actinomycin D, (2) daunorubicin, (3) doxorubicin,
(4) epirubicin, (5) pirarubicin, (6) idarubicin, (7) valrubicin, (8)
amrubicin, (9) aclarubicin, (10) mitoxantrone hydrochloride, (11)
pixantrone maleate, (12) sabarubicin hydrochloride, (13) annamycin,
and (14) berubicin hydrochloride
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Fig. 2 The chemical structures
of representative bleomycins
and enediynes. (15) Bleomycin
A2 sulfate, (16) NC-0604, (17)
calicheamicin-c10 , (18)
sporalide A, (19) sporalide B,
(20) cyanosporaside A, and (21)
cyanosporaside B
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Enediynes
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the compound is still in use in Japan and there are at least
six clinical trials in the USA and other countries currently
recruiting patients for Phase II to Phase IV trials. Calicheamicins linked to other monoclonal antibodies are also
being investigated. Phase I clinical trials of CMD-193, an
anti-Lewis Y antigen linked to a calicheamicin toxin for the
treatment of solid tumors were completed [88]. CMC-544
(inotuzumab ozogamicin), an anti-CD22 monoclonal antibody conjugated to N-acetyl-c calicheamicin 1,2-dimethyl
hydrazine dichloride is in Phase III trials in combination with
rituximab (NCT01232556 and NCT01564784) coupled to
other cytotoxic drugs. The conjugate was also in a recently
completed Phase II trial (NCT00868608) for the treatment of
indolent non-Hodgkin’s lymphoma. The detailed review by
Ricart [171] should be consulted for further information on
the impacts of monoclonal antibodies attached to N-acetyl-c
calicheamicin 1,2-dimethyl hydrazine dichloride and read
together with information in the 2012 update by Hamann
et al. [80].

Rapamycins and epothilones
The rapamycins and epothilones are two exemplary families of compounds that have demonstrated how modern
medicinal chemistry can be used to produce microbial
antitumor agents and other pharmaceuticals that are currently either approved for use or in clinical trials.
Rapamycins
The 31-membered macrocyclic antibiotic rapamycin (22a)
was originally reported in 1975 to be a potential antifungal
agent produced by the fermentation of Streptomyces hygroscopicus isolated from soil samples in Rapa Nui (Easter
Island) [11, 185, 220]. Rapamycin was unsuccessful as an
antifungal agent due to its immunosuppressant effects.
However, its potential as an antitumor agent against syngeneic murine tumors was later reported in 1984 by Sehgal
and coworkers [58] at Ayerst Research Laboratories. At
this time, the initial antitumor activity of rapamycin was
not further developed, but the rapamycin base structure
(22) has since led to the production of several molecules
with a variety of different pharmacological activities. In the
early 1990s, rapamycin’s molecular target (target of rapamycin, TOR) in yeast [87] and its mammalian homolog
(mTOR) [24] were discovered, leading to the development
of a wide variety of anticancer agents.
Initially, modifications were made at the carbon atom at
C43 on the rapamycin base structure (numeration as in Zech
et al. [243] rather than the alternative numbering system of
McAlpine et al. [136] based upon a comparison with
FK506, which would be a C40 substitution), leading to a
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The enediynes are a structurally unique class of antitumor
antibiotics, containing one of the most important approved
microbial compounds, calicheamicin c1I (17; Fig. 2). The
ten-membered calicheamicins were first reported in 1987
from the bacterium Micromonospora echinospora spp.
calichensis. Although calicheamicin c1I has sub-picomolar
in vitro cytotoxic activity it was not developed for many
years due to its extreme cytotoxicity. It and a close relative,
dynemicin A, became the progenitors of a new chemical
class of natural products, the enediynes. This class now
comprises 13 enediynes, including the recognition of the
much older neocarzinostatin chromophore [79] and the
rearrangement products of the putative enediynes sporolides A and B (18 and 19, respectively; Fig. 2) and cyanosporasides A and B (20 and 21, respectively; Fig. 2).
The enediyne core is composed of two acetylenic groups
conjugated by a double bond within either a nine- or tenmembered ring. Enediynes have been thoroughly investigated as both warheads and from a biosynthetic perspective
by the Wyeth discoverers [79] with an update in 2012 [80],
who described calicheamicin c1I as a representative tenmembered enediyne core, and members of Shen’s research
group at the University of Wisconsin-Madison [218].
The biosynthesis of the enediyne core structure remains
to be fully elucidated. Shen’s group demonstrated the lack
of biosynthetic divergence between the enediyne-specific
iterative type I polyketide synthases involved in the biosynthesis of nine- and ten-membered enediynes, by demonstrating that the same major product (a heptaene
metabolite) was made with all combinations of nine- and
ten-membered polyketide synthases and cognate thioesterase domains, indicating that there were no pathwayspecific interactions [95]. However, more recently, Belecki
et al. [14] speculated that heptaene was a shunt product and
showed that, in the absence of its cognate thioesterase
domain, a heterologously expressed CALE8 polyketide
synthase produces the expected octaketide polyene product
with a beta-hydroxy moiety. The biosynthesis of the
enediyne core will become clearer in the near future as the
role of the unique beta-hydroxy group in the cyclization of
enediynes is fully elucidated.
Upon activation, enediynes undergo an unprecedented
rearrangement and interact with DNA, resulting in cleaved
double-stranded DNA and subsequent cell death. In 2000,
the FDA approved gemtuzumab ozogamicin, an anti-CD33
humanized antibody linked to a semi-synthetic calicheamicin derivative as the first antibody-warhead conjugate
for use against chronic myeloid leukemia and possibly the
most potent approved antitumor drug to date. This particular construct was subsequently withdrawn by Wyeth in
2010 from the US market. However, at the time of writing,
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published), both in Phase I clinical trials. The structures of
these molecules either include the rapamycin core structure
or only have modifications at the C43 hydroxyl group,
avoiding both the FKBP-12 and TOR binding sites as
modifications anywhere else are thought to negate the basic
biological activity of these derivatives [111, 148].
Epothilones
The identification of the 16-membered macrolides epothilones A and B (24 and 25, respectively; Fig. 3) from
Sorangium cellulosum So ce90 by Reichenbach and Hoefle
in the mid to late 1980s [92, 93, 169], and their activity as
tubulin stabilizers (a similar mechanism to that of paclitaxel) [20], led to a surge in the number of chemical, biochemical, and genomic modifications to further explore the
utility of the epothilone base skeleton. These efforts led to
the FDA approval of Bristol-Myers’ 16-aza-epothilone B
(26; Ixabepilone; Fig. 3), a semisynthetic epothilone,
where the lactone bridge was replaced by an amide linkage,
for the treatment of breast cancer in October 2007.
Epothilone A was determined to be less active in preclinical trials than epothilone B [112], which has subsequently advanced to further stages of clinical development.
Interestingly the only difference between these two compounds is the presence of a methyl group at C12. Epothilone
B was in Phase III clinical trials for the treatment of
ovarian cancer, but these trials were discontinued by
Novartis Oncology in 2010 because the product did not
demonstrate a significant overall survival advantage. Currently, epothilone B is in Phase II trials for the treatment of
various cancers, including central nervous system metastases (NCT00450866), as well as prostate (NCT00411528)
and brain (NCT00219297). In addition, a synthetic epothilone derivative, sagopilone (ZK-EPO, 27; Fig. 3), a
close chemical relative of epo B is in Phase II trials under
Bayer-Schering for the treatment of melanomas
(NCT00598507) and other cancers. For further details on
the epothilones and their mechanisms of action, see the
latest review by Ferrandina and colleagues [64] in addition
to those by Danishefsky [45] and Altmann and colleagues
[6], which describe opportunities for the synthesis of epothilones and other derivatives.
Additional agents have been derived from work originating in Danishefsky’s laboratory at Memorial SloanKettering and further developed by Kosan Biosciences.
Phase II trials with (E)-9,10-didehydroepothilone D or
KOS-1584 (28; Fig. 3) for the treatment of non-small cell
lung cancer were completed but no recent development of
this compound has been reported [232]. Isoxazolefludelone
or KOS-1803 (29; Fig. 3) is another derivative that has
been jointly developed by Memorial Sloan Kettering and
Kosan Biosciences [37]. This compound is currently in
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total of four clinically approved drugs, sirolimus, everolimus, temsirolimus, and zotarolimus. In 1999, sirolimus
(rapamycin) (22a; Fig. 3) was approved as an immunosuppressive agent and now the same molecule is in Phase
I/II and II trials for the treatment of various cancers.
Similarly, everolimus (22b; Fig. 3) was initially launched
in 2004 as an immunosuppressive agent and subsequently
in 2009, 2010, 2011, and 2012 approved for the treatment
of kidney, brain, pancreatic, and breast cancers, respectively. In 2012, everolimus was released by Abbot to be
used as a stent in the treatment of coronary and peripheral
arterial diseases in the USA. This compound is also in
Phase III trials for diffuse large B cell lymphoma
(NCT00790036), liver (NCT01035229), and stomach
(NCT00879333) cancers. Temsirolimus (CCI-779) (22c;
Fig. 3) was approved as a treatment for renal carcinoma in
the USA in 2007, later approved in Japan in 2010, and is
currently in Phase II trials for the treatment of various
carcinomas in the USA, mainly under the support of the
National Cancer Institute. Zotarolimus (22d; Fig. 3) was
launched in the USA in 2005 for the treatment of arterial
restenosis and recently, the EU approved a stent containing
novolimus, a metabolite of rapamycin that has a C7hydroxy group.
Currently, Merck & Co. and Ariad Pharmaceuticals
have collaborated to develop another rapamycin derivative,
ridaforolimus (AP-23573); 22e; Fig. 3), which is in Phase
III clinical trials for the treatment of soft tissue carcinoma
(NCT00538239) and bone cancer (NCT00538239). Wyeth
Pharmaceuticals developed a rather interesting derivative
of rapamycin with a modified ring structure (23; Fig. 3),
ILS-920. The modification of the triene portion of the
molecule was designed to disrupt mTOR binding. However, ILS-920 appears to have a different target as it is a
non-immunosuppressive neurotrophic rapamycin analog
that has been reported to exhibit over a 900-fold higher
binding affinity for FKBP52 over FKBP12 compared to
that of rapamycin, promotes neuronal survival and outgrowth in vitro, and binds to the b1 subunit of L-type
calcium channels (CACNB1) [179]. ILS-920 was under
development for treating stroke [2] and a Phase I clinical
trial for the treatment of acute ischemic stroke
(NCT00827190) was completed. Interestingly, FKBP52
inhibition affects tubulin interactions in cells [28] and has
been exploited to screen natural products that inhibit the
formation of a complex between FKBP52 and androgen
receptors, which play a role in the progression of prostate
cancer [48]. Thus, ILS-920 may exhibit antitumor activity,
although no reports of such activity have been published
yet.
In addition, there are two prodrugs of rapamycin, Abraxis’ ABI-009 (a nanoparticle encapsulated formulation of
rapamycin) and Isotechnika’s TAFA-93 (structure not yet
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Fig. 3 The chemical structures of representative rapamycins and
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Geldanamycin derivatives and HSP90 inhibitors
The production of the benzoquinone ansamycin antibiotic
geldanamycin (31; Fig. 4) by Streptomyces hygroscopicus
var geldanus was first reported by The Upjohn Company in
1970 [50]. Subsequent studies revealed that this compound
had antitumor properties, which were initially thought to
result from the inhibition of the tyrosine specific kinase (vSrc) involved in regulating growth and cell proliferation as
well as several signal transduction pathways [216, 217]. In
1994 however, this compound was determined to bind to
heat shock protein 90 (HSP90) by Whitesell and coworkers
[233]. In 1997, Stebbins et al. reported that geldanamycin
specifically binds to an ATP site on HSP90, altering its
chaperone activity and indirectly leading to cell death
[192]. The history of the various modifications of geldanamycin and the initial development of tanespimycin
(17-AAG; Kosan Biosciences/Institute of Cancer Research
UK/NCI; 32) was described by Snader in 2005 [190], with
further details of the biological activity reported by
Kingston and Newman [109] in 2008, culminating in a
2012 review by Snader [191].

The geldanamycin derivative tanespimycin entered
clinical trials in 1999 as the first example of a signal
transduction modulator under the auspices of the NCI and
was subsequently licensed to Kosan Biosciences for
development. Phase III trials of tanespimycin for the
treatment of relapsed and refractory multiple myeloma
were completed and the compound is still in Phase II trials
for the treatment of thyroid cancer. The 18,21-dihydroderivative of tanespimycin, IPI-504 or retaspimycin
(Infinity Pharmaceuticals; 33; Fig. 4) [200], is in Phase II
clinical trials for the intravenous treatment of relapsed or
refractory stage IIIb or stage IV non-small cell lung cancer
(NSCLC) and other solid tumors. Due to the superiority of
retaspimycin, Infinity Pharmaceuticals is no longer developing the oral formulation of 17-aminogeldanamycin (34;
Fig. 4; IPI-493), which was in Phase I trials for the treatment of advanced malignancies [121]. In the future, we
expect reports of several other derivatives as the genes
involved in geldanamycin biosynthesis are known. Novel
analogs, such as thiazinogeldanamycin (35; Fig. 4) and
19-hydroxy-4,5-dihydrogeldanamycin (36; Fig. 4), have
already been reported from engineered strains of S. hygroscopicus JCM4427 in addition to other known derivatives [34].

Staurosporine derivatives
The indolocarbazole alkaloid staurosporine (37; Fig. 4)
was first identified as an antifungal agent by Omura et al. in
1977 [159] and later reported as a nanomolar protein kinase
C (PKC) inhibitor by Tamaoki et al. [201] in 1986. These
results led to several pharmaceutical companies searching
for selective PKC inhibitors via synthesis and screening
indolocarbazole compounds. For an in-depth review of the
discovery, biosynthesis, and biological activity of staurosporine and derivatives, one should consult the 2009
review by Nakano and Ōmura [147].
Currently, there are several variations of staurosporine
in clinical trials. The first is the rebeccamycin (a naturally
occurring halogenated staurosporine-like molecule) derivative becatecarin (38; Fig. 4), which has been in early
clinical trials at the NCI for the treatment of acute lymphocytic leukemia [22], small cell lung cancer [184], and
solid tumors [154]. Becatecarin was also in Phase III
clinical trials by Exelixis and Helsinn for the treatment of
bile duct tumors, but another antitumor agent exhibited
superior activity and the trials were discontinued. No recent
development has been reported for becatecarin. The second
variation is N-benzoyl staurosporine or midostaurin (39;
Fig. 4), which is a potent inhibitor of FMS-like tyrosine
kinase-3 (FLT-3) and is in Phase III clinical development
in combination with other antitumor agents for the
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Phase I clinical trials (NCT01379287) for the treatment of
solid tumors. A discussion of the chemistry leading to
KOS-1803 and other derivatives was published by Danishefsky’s research group in 2008 [38].
A collaboration between Endocyte (folate targeting) and
Bristol-Myers Squibb (epothilone derivative) led to the
development of a folate receptor-targeted molecule, epofolate (BMS-753493; 30; Fig. 3), in which folic acid was
linked to an aza-modified epothilone [119], with the synthetic information covered in a 2010 publication from
Endocyte (folate linker) and Bristol-Myers Squibb (azaepothilone) [222]. Epofolate was in early clinical trials at
Bristol-Myers Squibb for the treatment of patients with
advanced solid tumors. However, these trials terminated in
2011 but to date there have been no publications covering
the results or reasons for cessation.
With the availability of the genetic sequence of the S.
cellulosum myxobacterium, more combinatorial biosynthetic products with modifications to the epothilone base
skeleton are being reported. For example, Menzella and
coworkers [139] have reported the whole-cell biocatalysis
of novel epothilone analogs using Escherichia coli. In
addition, Tang and colleagues have reengineered epothilone polyketide synthases found in S. cellulosum and
introduced them into another myxobacterium (Myxococcus
xanthus) that is more amenable to genetic manipulation
[204]. For additional details on epothilones produced via
genetic engineering, see the review by Park and coworkers
[161].
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45. Romidepsin

19-hydroxy-4,5-dihydrogeldanamycin, (37) staurosporine, (38) becatecarin, (39) midostaurin, (40) lestaurtinib, (41) enzastaurin, (42)
K-252A, (43) suberoylanilide hydroxamic acid (SAHA), (44)
trichostatin A, and (45) romidepsin
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Histone deacetylase inhibitors
Histone deacetylases (HDACs) are typically found in multiprotein complexes that regulate transcription by altering the
acetylation of histone proteins and other non-histone targets
[96, 100, 238]. The expression of HDACs is altered in tumors,
making them useful targets for preventing epigenetic abnormalities that lead to cancer. A total of 18 human HDACs [49,
54, 75, 104, 114, 160] have been identified and can be divided
into four classes (I–IV) based on their homology to known
yeast HDACs, subcellular localization, and enzymatic activities. Class I and II are Zn2?-dependent amidohydrolases that
share some degree of sequence homology and are homologous
to yeast Rpd-3 and Hda1, respectively. Class IV is also Zn2?-

dependent, homologous to yeast HDAC HOS3, and has a
known member, HDAC11, that shares weak homology with
the catalytic core regions of Class I and II enzymes [160]. The
Class III sirtuins are outliers as they require the cofactor
NAD?, have different cellular localizations depending upon
the isoform(s), and are homologous to the Sir2 yeast protein
[140].
HDAC inhibitors (HDACis) typically consist of a tripartite structure consisting of an aromatic enzyme binding
group, a hydrophobic spacer group, and an inhibitor group
[170, 239, 241]. Suberoylanilide hydroxamic acid (SAHA,
43; Fig. 4) is a good example of an HDACi with this tripartite structure as it consists of a 6-carbon aliphatic chain
(the spacer), the inhibitory end being the zinc-binding
hydroxamic acid, and the aromatic enzyme binding group
being the phenyl-amino ketone group. SAHA is a synthetic
hybrid polar compound structurally related to the potent
(nanomolar level) microbial HDACi trichostatin A (TSA,
44; Fig. 4) [172, 173, 240], which was isolated from S.
hygroscopicus in 1976 and determined to be an antifungal
agent [212]. By combining the structure of TSA and data
from hybrid polar compounds, SAHA was synthesized and
tested as an HDACi. In 2006, SAHA was approved by the
FDA to be used as an oral treatment for lymphoma under
the generic name vorinostat. SAHA is currently in multiple
Phase I–III trials for the treatment of a variety of cancers.
The only other approved HDACi is romidepsin
(FK228), a fermentation product isolated in 1994 from the
Gram-negative bacterium Chromobacterium violaceum
isolated from a Japanese soil sample [215]. Romidepsin is a
bicyclic depsipeptide with an unusual disulfide bond connection between a thiol and D-cysteine. In 1998, romidepsin was identified as a broad-spectrum HDACi that induces
epigenetic changes in a variety of cancer cells [146].
Furumai et al. [67] demonstrated that romidepsin was a
naturally occurring prodrug that inhibited Class I HDACs
presumably by the reduced sulfhydryl group(s) interacting
with the active site Zn2?. In 2009 and 2011, romidepsin
was approved by the FDA for the treatment of relapsed
cutaneous cell lymphoma and relapsed/refractory peripheral T-cell lymphoma, respectively. Romidepsin has also
completed early clinical trials for the treatment of several
cancers, including solid tumors (NCT00019318), lung
(NCT00086827), thyroid (NCT00098813), and prostate
(NCT00106418) cancers, mainly under the auspices of the
NCI. For an in-depth overview of the preclinical and
clinical development of romidepsin, see the 2012 review by
Harrison and coworkers [82].
With the sequence of the gene clusters involved in
romidepsin biosynthesis now known, reengineering strategies are predicted to produce several analogs via fermentation [36, 167]. A patent (PCT/US2008/053473) was filed
by Cheng on the sequences involved in romidepsin
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treatment of acute myeloid leukemia (NCT00651261) [65].
Midostaurin is also in Phase I and II trials for the treatment
of systemic mastocytosis (NCT00233454) [72] and adenocarcinoma (NCT01282502), respectively. Lestaurtinib
(40; Fig. 4) is another derivative that has completed several
Phase II trials at Cephalon for the treatment of myeloproliferative diseases. This agent is also in Phase I trials at the
NCI for the treatment of recurrent or refractory high-risk
neuroblastoma in pediatric patients (NCT00084422). Enzastaurin (41; Fig. 4), an open-ringed, derivatized version
of the base staurosporine carbocycle, is a selective PKC-b
inhibitor in Phase III clinical development at Eli Lilly &
Co as oral treatment of diffuse large B-cell lymphoma
(NCT00332202). This agent was compared to the alkylating drug lomustine (CCNU) in Phase III trials
(NCT00295815) after a successful Phase II trial for patients
with recurrent glioblastoma multiforme. However, the
study was terminated due to the low median overall survival. Because enzastaurin was more tolerated than lomustine,
enzastaurin may be more successful in other combination
therapies [234]. Enzastaurin is also in Phase II trials both alone
and in combination with other agents for the treatment of
gliomas (NCT00475644), renal cancer (NCT00709995), and
a variety of lymphomas (NCT00475644, NCT00542919, and
NCT00451178). Finally, a PEGylated version of the known
indocarbazole K252a (42; Fig. 4) has completed Phase II
clinical trials for the treatment of the proliferative disease
psoriasis vulgaris at Creablis SA (NCT00995969 and
NCT01465282).
New derivatives with biological activity are still being
synthesized via synthetic modifications to a variety of
positions on the indocarbazole base structure [7, 8].
However, with the increasing number of known gene
clusters and reduced specificity of their corresponding
biosynthetic enzymes, combinatorial biosynthesis can be
expected to provide a wider pool of structurally diverse
indocarbazoles candidates with antitumor properties [180].
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Marine sources
The ocean continues to be one of the largest unexplored
sources of specialized metabolites due to its inaccessibility
as more than 70 % of the Earth is covered by water. The
rich diversity found in the world’s oceans has provided a
plethora of structurally diverse specialized metabolites
with a variety of carbon skeletons and degrees of halogenation. Although numerous compounds have been reported
with cytotoxic activities, very few have been definitively
proven to originate from invertebrates, but there is sufficient evidence invoking microbial production of a significant number of these bioactive metabolites [124]. A
significant number of compounds have been isolated from
blue-green algae (cyanobacteria), other bacteria [145], and
fungi that were isolated from sediments (both shallow and
abyssal) or from invertebrates, where there is no question
of the actual producer as fermentations produced the
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compounds of interest. Over the past 30–40 years, a
number of these cytotoxic compounds have been isolated
and tested for biological activity by the NCI. Here, we
describe a select number of marine natural products that
entered, are still in clinical trials, or have been approved by
the FDA (or corresponding agencies in other countries) and
who either have or may well have, a microbe involved in
their production.

Bryostatins, dolastatins, and analogs
Bryostatin and analogs
Bryostatin 1 (46; Fig. 5) and dolastatin 10 (47; Fig. 5)) are
two prime examples of marine-derived compounds that
required heroic efforts to isolate enough material for initial
clinical trials from the invertebrate Bugula neritina and
nudibranch Dolabella auricularia, respectively. Details of the
early to relatively late history of the bryostatins can be found in
reviews by Newman [149] and Trindade-Silva [208], and by
Flahive and Srirangam [66] for the dolastatins.
Bryostatins are a family of 20 macrocyclic lactones that
originate from the marine invertebrate Bugula neritina. All
metabolites in this family generally share a 20-member
macrolactone core and three remotely functionalized
polyhydropyran rings. Bryostatins differ from one another
by substitution at C7 and C20 and placement of the c-lactone at either C19 or to C23 in the polyhydropyran ring.
These metabolites are thought to be produced by the
uncultured microbe Candidatus Endobugula sertula, but
definitive proof was lacking at the time of the discovery of
this microbe. The most promising piece of evidence at that
time was the reduction of the amount of bryostatin 1 in B.
neritina colonies treated with antibiotic-treated larvae [46,
126]. However, later work by Haywood and coworkers led
to the isolation and cloning of the gene cluster involved in
the biosynthesis of the base ring structure of bryostatins but
the large, trans-AT PKSs have deterred their heterologous
expression at this time [127].
The most studied member of the bryostatin family is
bryostatin 1. Phase I and II trials against hematological
cancers have been completed with this agent either alone or
in conjunction with a cytotoxin. As a result of these trials,
bryostatin 1 appeared to be more promising when administered in combination with other antitumor agents, such as
paclitaxel and vincristine [13, 143]. Currently, there are
three Phase II trials with bryostatin plus a cytotoxin or
signal transduction inhibitor listed in the NCT clinical trials
database but all have an ‘‘unknown’’ status. Thus, these
trials have probably ceased, though there is one Phase I
trial (NCT00112476) with temsirolimus and bryostatin
listed as recruiting as of the end of 2012.
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biosynthesis to generate analogs [35]. In the meantime, a
variety of synthetic methods have been employed [73,
122]. In 2008, Wen and colleagues used a macrolactamization protocol to form the amide bond in the larger ring
last instead of macrolactonization to form the lactone last,
bypassing the challenges in the macrolactonization of less
reactive substrates to produce synthetic romidepsin analogs
[229]. Additional modifications are also being made to the
HDACi tripartite skeleton to develop more selective
inhibitors [178, 193, 206], including those without a Zn2?chelating group in order to prevent undesirable interactions
with other metalloenzymes [221]. For a summary of other
reported HDACis produced by bacteria, see the 2012
review by Ho and coworkers [91].
In addition, Di Maro et al. [52] demonstrated the isosteric replacement of the synthetically challenging (3S,4E)3-hydroxy-7-mercaptoheptenoic acid (shown in red in 45;
Fig. 4) in order to make romidepsin analogs from the easily
assembled starting materials, L-aspartic acid and a cysteamine. To accomplish this, the trans double bond was
replaced by an isosteric amide group and the macrolide
lactone was replaced by an amide linkage. However, the
resulting isosteres were not as potent as romidepsin. In
2009, Bowers and coworkers [23] also reported the synthesis of an amide isostere of romidepsin but the compound
exhibited 50-fold lower inhibition against HDACis. Based
on computational analysis, these results were speculated to
arise from small differences in the position of the free thiol
group when the molecule was docked in the enzyme active
site. Thus, understanding the subtle differences between
the structures of HDACi analogs may confer changes in
their potency and provide direct routes to inhibitors with
enhanced activity.
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Dolastatins and analogs
The linear pentapeptide dolastatin-10 was initially isolated
from the sea hare Dolabella auricularia, and then isolated
from a cyanophyte of the genus Symploca many years later
[130]. Thus, in contrast to the bryostatins, the actual producing organism could be isolated and identified. Dolastatin 10 was later found to inhibit the assembly of
microtubules [56] and Phase II clinical trials for the treatment of several solid tumors, including pancreatic
(NCT00003677) and kidney (NCT00003914) were completed. However, these trials revealed that dolastatin 10
exhibited minimal responses in cancer patients and no
recent development of this compound has been reported
[108, 165, 224]. Phase II clinical trials for the treatment of
non-small cell lung cancer (NCT00061854) and metastatic
soft tissue sarcoma (NCT00064220) of auristatin PE (51;
Fig. 5), a synthetic derivative of dolastatin 10, have been
completed, but no recent developments has been reported
for this agent. However, an anti-CD30 antibody-conjugated
monomethyl auristatin E (brentuximab vedotin or SGN-35,
Seattle Genetics) was approved by the FDA in 2011 for the
treatment of various lymphomas. The details of the
development of brentuximab vedotin are discussed in the
2012 review by Younes and colleagues [242].
Currently, several other antibody-conjugates using a
variety of stable linker systems attached to monomethylauristatin E (licensed from Seattle Genetics) are either in or
approaching clinical trials. Phase II clinical trials for the
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treatment of breast cancer (NCT01156753 and
NCT00704158) and resectable stage III or stage IV melanoma have been completed for CR011-vcMMAE (Curagen
Corp), where monomethyl aurostatin E is linked to a
CR011 antibody against the melanoma antigen glycoprotein NMB, which is also expressed in some metastatic
breast cancers. The results of NCT01156753 were promising as efficacy was shown in the following cohorts:
patients with triple-negative breast cancer, triple-negative
breast cancer and significant glycoprotein NMB expression, and only high levels of glycoprotein NMB [27].
Triple negative breast cancers do not express any of the
three receptors (estrogen, progesterone or her-) commonly
found in most breast carcinomas and are therefore difficult
to treat with current receptor-targeted drugs. Thus these
findings are of definite import for the design of treatment
protocols.
A Phase II trial for the treatment of prostate cancer
(NCT1695044) using PSMA-ADC (Progenics), where
monomethyl auristatin E is tethered to a prostate-specific
membrane antigen, is in progress. A Phase I trial of DCDS4501A (an anti-CD79b monoclonal antibody linked to
monomethyl auristatin E via a protease cleavable linker;
Genentech) in conjunction with rituximab is underway for
the treatment of non-Hodgkin’s lymphoma and chronic
lymphocytic leukemia (NCT01290549). Using the same
linker and warhead, but to a different monoclonal antibody,
a humanized IgG1 anti-CD-22, Genentech are sponsoring a
Phase II trial of this agent (DCDT-2980S) against follicular
and diffuse large B-cell lymphomas, in conjunction with
other monoclonal antibodies as part of a complex treatment
regimen (NCT01691898). Phase I clinical trials for the
treatment of a variety of cancers using other antibody-auristatin conjugates utilizing different linkers, such as MLN0264 (Millenium Pharmaceuticals), DSTP-3086S (Genentech), AGS-22M6E (Astellas Pharmas Inc/Seattle Genetics/
Agensys Inc), and AGS-5 ADC (Seattle Genetics/Agensys
Inc), are also underway or actively recruiting. Thus, the
promising concept of linking auristatin and derivatives to
monoclonal antibodies targeted at specific epitopes may
lead to an increase in the number of agents and derivatives
in cancer therapy in due course.

Trabectedin
The tetrahydroisoquinoline alkaloid trabectedin (ET-743,
PharmaMar; 52; Fig. 5) is the first compound ‘‘directly
from the sea’’ to be approved for the treatment of cancer. In
1969, ethanol extracts of the Caribbean tunicate Ecteinascidia turbinata were first reported to have antiproliferative
properties by Sigel and colleagues [188]. It took at least
another 17 years for the first report of the isolation and
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Several bryostatins and analogs have been synthesized
using methods such as function-oriented synthesis as
employed by Wender and other workers to develop simplified analogs with comparable or improved activities [51,
209, 230, 231], but the economical production of bryostatins via synthesis requires further investigation. Bryostatins
2 (48; Fig. 5) [61], 3 (49; Fig. 5) [157], and 7 (50; Fig. 5)
[105, 132] have been made via total synthesis utilizing
more than 70 steps. To address this problem, Trost and
coworkers [210] have developed a 39-step, stereoselective
synthesis of the bryostatin polyhydropyran ring C and the
Keck group recently published an impressive, asymmetric
60-step synthesis of bryostatin 1 [107].
Bryostatins have a high binding affinity for protein
kinase C (PKC) isozymes [113], which have been used to
identify specific targets and develop other analogs [106].
Furthermore, PKC activity plays a major role in learning
and memory [1], and from animal studies, bryostatin 1 may
have potential to treat cognitive diseases [198, 199, 227].
Bryostatin 1 was approved for a Phase II trial
(NCT00606164) for the treatment of Alzheimer’s disease
at the Blanchette Rockefeller Neurosciences Institute, but
there have been no updates on the progress of this study.
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Trabectedin is structurally related to the saframycin and
safracin classes of known antibiotics (see 56 and 57 in
Fig. 5 for examples of these structural classes, respectively), which share similar tetrahydroisoquinoline frameworks. Thus, trabectedin and other compounds were
thought to have microbial components involved in their
production. Recently, Rath and coworkers [168] have
demonstrated that a microbial consortium derived from
Ecteinascidia turbinata via metagenomic sequencing was
the probable producer of trabectedin. Using the known
gene clusters of the saframycin [123] and safracin [219]
metabolites as markers, the contig encoding the NRPS
biosynthetic enzymes involved in trabectedin production
was identified as well as the producing organism c-proteobacterium Candidatus Endoecteinascidia frumentensis
(AY054370). These results confirm previous reports speculating that bacterial candidates from Caribbean and
Mediterranean E. turbinata [144, 164] are involved in
trabectedin production as Candidatus Endoecteinascidia
frumentensis was found in E. turbinata in both geographic
locations. With these new findings, we expect to see more
reports on the genetic engineering of the trabectedin biosynthetic genes to produce several new analogs with
promising biological activity.

Kahalalide F
The cyclic depsipeptide kahalalide F (58; Fig. 6) is one of
the most active antitumor metabolites of the kahalalide
family that was first isolated from the herbivorous Sacoglossan mollusk, Elysia rufescens, which grazes on the
green macroalga, Bryopsis sp. [78]. Following its isolation
and identification, kahalalide F was also reported to be
found in less concentrated amounts in the alga compared to
the mollusk based on wet weight [77]. These observations
suggest that this compound is likely to be a specialized
metabolite produced by a symbiont. Total synthesis has
mainly been used to access kahalalide F and derivatives
using solid phase peptide techniques [101, 103, 128].
However, Hill and coworkers filed an international PCT
application, in which they describe the isolation of kahalalide F and other analogs from Vibrio mediterranei/
shilonii isolated from Bryopsis and E. rufescens [89].
Therefore, large-scale fermentation may be able to generate renewable supplies of the depsipeptide. For more
details on the isolation, structural elucidation and biological activity of kahalalide F and analogs, see the 2011
review by Gao and Hamann [68].
In the 1990s, kahalalide F (PM-92102) was licensed to
PharmaMar by the University of Hawaii and entered preclinical development. Kahalalide F entered Phase I clinical
trials in Europe in December 2000 for the treatment of
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structural characterization of ecteinascidin derivatives to be
published [94], followed by two papers in 1990 [175, 235].
The compound was later licensed to the Spanish pharmaceutical company PharmaMar where its isolation was
optimized from large-scale collections from marine environments and also from in-sea and on-land aquaculture of
the source tunicate. Several years of aquaculture/isolation
provided enough material for the initial and early clinical
trials [41]. Simultaneously, synthetic efforts were also
made to obtain more trabectedin. The first total synthesis
was accomplished by Corey’s research group, which was
inspired by the probable biosynthetic route to trabectedin
[40]. Several other syntheses of trabectedin were published
but ultimately did not meet the requirements for the commercial production of trabectedin. However, PharmaMar
developed a short, semisynthetic synthesis to produce gram
quantities of trabectedin [43] starting with the antibiotic
cyanosafracin B (53; Fig. 5) [99], a fermentation product
of a marine-derived Pseudomonas fluorescens [42].
Trabectedin has since been developed by PharmaMar
and approved by the EMEA in September 2007 for the
treatment of sarcoma and in 2009 for the treatment of
ovarian cancer. For more information about the discovery
and mechanism of action of trabectedin, see these recent
reviews [44, 162]. In 2009, PharmaMar also launched this
drug in the Philippines for the treatment of ovarian cancer,
then in 2011 trabectedin was approved in Japan for the
treatment of malignant soft tissue tumors accompanied
with chromosomal translocation. In the US, an application
was filed for the approval of the use of trabectedin in
combination with docetaxel for the treatment of recurrent
ovarian cancer. However, the FDA recommended that an
additional Phase III trial be conducted, which led to the
voluntary withdrawal of the New Drug Application by
Johnson & Johnson.
Trabectedin is still in many Phase III and earlier clinical
trials for the treatment of various cancers. PharmaMar has
also developed the trabectedin analog lurbinectedin
(PM01183, 54; Fig. 5), which has a tetrahydro-b-carboline
moiety instead of the tetrahydroisoquinoline present in ring
C. Phase I and II clinical trials with lurbinectedin are
currently underway for the treatment of advanced tumors
(NCT01405391)
and
metastatic
breast
cancer
(NCT01525589), respectively. A Phase II trial against
Ewing’s sarcoma (NCT01222767) using the closely related
compound zalypsis (PM00104, 55; Fig. 5), bearing structural similarities to ET-743 and the jorumycins with a trifluoromethyl-phenyl substituent on the Southern edge, just
completed. This compound was also in two European
Phase II trials EudraCT Number 2010-020994-18 for the
treatment of cervical carcinoma (completed but no published details as yet) and EudraCT Number 2009-01605440 against refractory melanoma.
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androgen-independent prostate cancer and is currently in
Phase II clinical trials against a variety of cancers including, hepatocellular carcinoma, non-small cell lung cancer,
androgen-independent prostate cancer, and malignant
melanoma. However, aside from a Phase II trial in Spain
(EudraCT Number 2004-001253-29) for the treatment of
non-small cell lung cancer that has been ongoing since

2004, there have been no recent developments reported for
this compound for the treatment of cancer. Most antitumor
agents induce programmed cell death or apoptosis, but
kahalalide F appears to have a unique mechanism of action
of primarily inducing oncosis [186, 197], which is the
process of passive cell death accompanied by swelling.
Several other kahalalide F targets have been identified to
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Aplidine
The isolation of the cytotoxic depsipeptide aplidine (dehydrodidemnin B, 60; Fig. 6; PharmaMar) from the
ascidian Aplidium albicans was first reported by Rinehart
and colleagues in 1991 [174]. This compound is structurally similar to didemnin B (NSC-325319, 61; Fig. 6),
which was isolated from the Caribbean tunicate Trididemnum solidum and reported to have antitumor and
antiviral properties [176]. A detailed history of the isolation, biological activity, and clinical development of the
didemnin family as well as aplidine can be found in the
2012 review by Lee and coworkers [120].
The only difference between the structures of aplidine
and didemnin B is the presence of a lactyl hydroxyl group
in the terminal side chain of didemnin B instead of its
corresponding ketone form in aplidine. Interestingly, this
small structural difference has resulted in aplidine exhibiting stronger antitumor effects and lower cardiotoxicity
compared to didemnin B [125], which was the first marine
natural product to enter clinical trials. Didemnin B was not
further developed beyond Phase II clinical trials due to the
lack of response, acute cardiotoxicity, and neurotoxicity
[117]. Aplidine has become PharmaMar’s second most
advanced compound behind trabectedin as it has completed
Phase II trials for the treatment of aggressive non-Hodgkin
lymphoma (NCT00884286) and Phase III trials in combination with dexamethasone (NCT01102426) for the treatment of multiple myeloma [42].
Chemical synthesis has been used to produce aplidine
[177] for clinical studies however bacterial fermentation
may eventually be used to produce this compound, as other
tunicate-derived didemnins have recently been demonstrated to be produced by free-living and potentially symbiotic bacteria [213]. Xu and coworkers [237] sequenced
the genome of the marine a-proteobacteria Tistrella mobilis, revealing the didemnin gene cluster, and using
imaging mass spectrometry, the real time conversion of
didemnin X and Y precursors to didemnin B was observed.

With the identification of the didemnin B gene cluster, it
may be feasible to use genetic engineering to create
renewable supplies of aplidine via microbial fermentation.
Furthermore, metagenomic analyses of Aplidium albicans
using Tistrella mobilis gene clusters as markers, may lead
to the identification of the bacterial genes involved in
aplidine biosynthesis in the tunicate as it has not yet been
proven that the same free-living microbe produces both
aplidine and its reduced congener, didemnin B.

Salinosporamide A
The cytotoxic proteasome inhibitor salinosporamide A
(NPI-0052, 62; Fig. 6; Nereus Pharmaceuticals) is one of
the most interesting natural products as it has been isolated
from cultivatable deep-sea, free-living microbes [62]. Its
producing strain, Salinispora tropica, was isolated from
deep-sea sediment collected in the Bahamas. Salinispora
tropica is a marine streptomycete that can be propagated
via saline fermentation and has truly showcased the capabilities of marine bacterial fermentation of natural products. Notably, bacterial fermentation afforded enough
material (450 mg/l) for the clinical development of this
compound [211], representing the first time in which saline
fermentation was successfully performed on any scale with
a marine-sourced microbe.
Salinosporamide A is structurally similar to the terrestrial bacterial product lactacystin (63; Fig. 6) and the lactacystin-biorearrangement derivative, omuralide (64;
Fig. 6), the prototypical inhibitor of the 20S proteasome
[53, 63]. The cytotoxicity of salinosporamide A is derived
from its irreversible binding to the 20S proteasome through
an ester linkage between its b-lactone carbonyl carbon and
the hydroxyl group of an N-terminal threonine residue in
the proteasome. Subsequent hydrolysis of the b-lactam of
salinosporamide A leads to an intramolecular nucleophilic
addition to the chloroethyl group, resulting in the elimination of chlorine to form a cyclic ether, which prevents
the cleavage of the proteasome-inhibitor ester bond [74]. In
addition, the unusual cyclohexene ring in salinosporamide
A enhances its hydrophobic interactions with the proteasome S1 specificity pocket, further preventing the hydrolysis of the proteasome-inhibitor ester bond.
Salinosporamide A also inhibits NF-jB activation, which
is activated by proteasome activity [3].
Phase I clinical trials sponsored by Nereus Pharmaceuticals with Salinosporamide A commenced only 3 years
after the report of its discovery, for the treatment of
advanced malignancies (NCT00629473) and multiple
myeloma (NCT00461045). A Phase I trial for the treatment
of solid tumors and lymphoma has been completed
(NCT00396864). Because studies have shown that

123

Downloaded from https://academic.oup.com/jimb/article/40/11/1181/5994885 by guest on 21 February 2022

play a role in inducing cytotoxic activity, such as lysosomes [69, 197], plasma membrane [197], and proteins
involved in the Erb3 and phosphatidylinositol 3-kinaseAkt/PKB signal pathways [102, 166].
A closely related isomer of kahalalide F, isokahalalide F
(PM-02734, elisidepsin, 59; Fig. 6) has also been reported
to be cytotoxic and was produced by solid-phase synthesis
and developed at PharmaMar [42]. A completed Phase I
clinical trial (NCT00884845) with this compound in
combination with erlotinib for the treatment of solid tumors
demonstrated that the combination was not efficacious
[71].

1199

1200

Carfilzomib
In 1992, Hanada et al. reported [81] the isolation and
antitumor properties of the tetrapeptide epoxomicin (67;
Fig. 7), a metabolite of an unidentified actinomycete strain
No. Q996-17 with an epoxy-b-aminoketone moiety similar
to that of eponemycin (68; Fig. 7). Epoxomicin entered
preclinical trials with Bristol-Myers Squibb Research
Institute in Tokyo but was dropped due to its unknown
mechanism of action. In 1999, the Crews’ group at Yale
University published both the synthesis of epoxomicin
[189] as they were not able to obtain its producing strain
and the results of a labeling study [138], in which they
were able to demonstrate that this compound inhibited the
20S proteasome. Notably, they did not observe any crossinhibition with other proteases.
An N-terminal threonine residue in the proteasome was
determined to covalently attach to epoxomicin by forming
a morpholino ring adduct with the carbonyl of the epoxy
ketone moiety. Other proteases typically do not have active
sites at the N-terminus to form an N-morpholino ring.
Thus, epoxomicin is very specific for the 20S proteasome.
With this mechanism of inhibition in mind, the Crews’
group in conjunction with Proteolix synthesized many epoxomicin derivatives. The final drug candidate, carfilzomib
(69; Fig. 7), was the initial compound designed by Crews
(YU-101, 70; Fig. 7) [57] with a morpholino end group
attached to improve its solubility, oral availability, and
ADME properties [47]. This compound was approved by
the FDA in July of 2012 for the treatment of multiple
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myeloma, with an analysis of the clinical trials leading to
FDA approval published by McCormack [137]. As of July
2013, there are 53 ongoing clinical trials covering the
treatment of hematological cancers at Phases I–III.
The story of carfilzomib demonstrates the power of modern
synthetic chemistry coupled with key biochemical pull-down/
binding experiments to identify a previously unknown target
of a microbial product. In addition, synthesis enabled subsequent modification of the base molecule to produce a viable
drug candidate. Effectively 90 % of the epoxomicin backbone, including the ‘‘warhead end’’, is a part of the structure of
the synthetic drug, representing a prime example of a modified
natural product skeleton leading to a drug entity. Importantly,
carfilzomib is the second approved protease inhibitor after
bortezomib (71; Fig. 7) but the first to not cause painful side
effects, such as peripheral neuropathy [9].

Halichondrin B
In 1986, Uemura and coworkers [90] reported the isolation
of the structurally complex natural product halichondrin B
(72; Fig. 7) from 600 kg of marine sponge Halichondria
okadai. The structural class of this molecule implied that it
may well be produced by a protist, though the involvement
of other microbes is possible. This compound exhibited
potent cytotoxic activity against B-16 melanoma cell lines
(IC50 = 0.09 nM) and in 1991, Bai and coworkers [10]
demonstrated that halichondrin B functioned as a tubulin
destabilizing agent.
At that time, total synthesis of halichondrin B seemed
impossible. However in 1992, Kishi and coworkers [4]
reported that they had synthesized halichondrin B and later
worked with chemists and biologists at Eisai to develop
over 200 derivatives of the natural product and evaluate
their in vitro and in vivo activities. During this time, scientists at the NCI were also independently working with
New Zealand scientists to isolate enough halichondrin B
from the deep water New Zealand sponge Lissodendoryx
sp. for preclinical studies. In 1998, scientists at both the
NCI and Eisai collaborated to evaluate the two best synthetic analogs from Eisai and pure halichondrin B from the
deep-water New Zealand collections. One of the synthetic
compounds, a truncated halichondrin B analog, now known
as eribulin (73; Eisai; structural similarities to 72 are shown
in red in Fig. 7), showed significantly more potent activity.
Specifically, eribulin exhibited an order of magnitude
higher potency than halichondrin B against DLD-1 human
colon cancer cells [110] and similar profiles against the
NCI60 tumor cell lines. Based on its antitumor activity,
eribulin was evaluated in clinical trials as a mesilate salt.
In 2010, eribulin mesilate was approved and launched in
the US for the treatment of patients with metastatic breast
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combinations of HDAC and proteasome inhibitors have
significant therapeutic potential [142, 163], Phase I clinical
trials are also being performed in combination with vorinostat for the treatment of non-small cell lung cancer,
pancreatic cancer, and melanoma (NCT00667082). Thus
far, the results of this combination have been positive as it
exhibited highly synergistic antitumor activity and was
deemed to be as safe as taking salinosporamide A and
vorinostat separately [141].
Several synthetic methods have been used to generate
many salinosporamide A derivatives [33, 153, 182]. However,
the most interesting analog has been derived via the genetic
engineering of the salinosporamide A gene cluster. Notably,
the production of the fluorinated metabolite fluorosalinosporamide A (65; Fig. 6) and salinosporamide X7 (66; Fig. 6)
by the Moore group demonstrated the utility of genetic engineering and chemical synthesis to produce novel marinederived analogs [59]. Fluorosalinosporamide A was determined to be a slow reversible inhibitor of the 20S proteasome,
whereas salinosporamide X7 was nearly three times more
cytotoxic than salinosporamide A.
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Fig. 7 The chemical structures of epoxomicin and halichondrin B and representative derivatives. (67) Epoxomicin, (68) eponemycin, (69)
carfilzomib, (70) YU-101, (71) bortezomib, (72) halichondrin B, and (73) eribulin

cancer who have received and failed at least two chemotherapeutic regimens. A year later, this compound was
approved in the EU and Japan for the treatment of breast
cancer and later launched in Japan. Eribulin mesilate is
currently in many clinical trials against various carcinomas
either as a single agent (NCT01676818) or in combination
with other compounds (NCT01534455, NCT01554371).
To date, the actual producer is not yet identified but the fact
that halichondrins have been isolated from many different
classes of the Porifera from many geographical sites and
depths, points to a microbial and or protist source.

Genetic blueprints for the production of microbial
metabolites
For over 50 years, large and small pharmaceutical companies fermented millions of soil isolates in order to find
new microbial agents and over time realized that they were

isolating the same metabolites. This chemical redundancy
is reflected by the significant decrease in the number of
new secondary metabolites from terrestrial microbes that
have been reported since the late 1960s. For a multiplicity
of reasons, most companies decided to jettison their fermentation-based discovery programs from roughly the
middle of the 1980s to early 2000s. However, with the
development of new sequencing technologies, we now
have access to microbial genomes and can use a variety of
tools to fully elucidate and activate biosynthetic pathways.
Rapidly evolving next-generation sequence (NGS, postSanger sequencing) technologies have led to the quick and
inexpensive high-throughput sequencing of multiple
microbial genomes in parallel, providing biologists and
chemists with high volumes of sequence data for genes
involved in natural product biosynthesis. Sanger sequencing can provide read lengths of approximately 1,000 bp/
read at a cost of at least $500/Mbp, but now some NGS
technologies can rapidly produce at least 13–36 bps/read
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other microbes has been a successful method for ‘‘awakening’’ cryptic gene clusters. Recently, Nützmann and
coworkers [155] reported the cocultivation of the soildwelling Streptomyces rapamycinicus (formerly S. hygroscopicus) with the fungus A. nidulans, activating a silent
fungal polyketide synthase gene cluster involved in producing orsellinic and lecanoric acids as well as the
cathepsin inhibitors F-9775A and F-9775B. The 2013
review by Ochi and Hosaka [156] should be consulted for
an in-depth analysis of the current methods used to activate
cryptic gene clusters.
The limited diversity of currently ‘‘culturable’’ microbes
also contributed to the decline in the discovery of new
natural products. Now, metagenomic sequencing has
become very powerful in identifying gene clusters from
environmental samples of mixed, unculturable organisms,
providing further insight on the interactions between
organisms within a community [225]. This will be extremely useful for identifying the biosynthetic gene clusters of
marine natural products, for which one major challenge is
working with unculturable organisms. Recently, Donia and
coworkers [55] sequenced the complex microbiome
underlying the symbiosis between the tunicate Lissoclinum
patella and the uncultivated cyanobacterium Prochloron
didemni, which demonstrated the secondary metabolite
symbiosis between these organisms and also helped to
identify other symbiotic bacteria for future studies. Metagenomic sequencing has also been used to direct culturing conditions such as the microbiota of the medicinal
leech Hirudo verbena, which includes Aeromonas veronii
and a Rikenella-like bacterium. High expression levels of
mucin and glycan utilization genes were found in the Rikenella-like bacterium, and growing the microbe in media
containing mucin instead of glucose led to the growth of
pure cultures of this microbe [21]. Lastly, with the amount
of data generated by NGS technologies, we expect an
increase in the number of new databases thus facilitating
the search for genes involved in the production of specific
metabolites [26, 39, 97].

Plant metabolites and endophytes
Within the past two decades, there has been a significant
increase in the number of reports of endophytes (microbes
that live inside the living tissues of plants without having
deleterious effects) producing valuable therapeutic plant
secondary metabolites. For every one of the approximately
350,000 plant species on earth, each plant serves as a host
to one or more endophytes [194]. This is a trend that was
identified in the marine area where natural products that
were initially thought to be invertebrate-derived were later
found to be produced by symbiotic or commensal
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for well under $3.00/Mbp [187]. As a result of the plummeting costs of sequencing, several large-scale sequencing
initiatives have been initiated, such as the Genomic
Encyclopedia of Bacteria and Archea [236] and the Human
Microbiome Project [18]. As a result, the number of
complete whole microbial genome sequences has skyrocketed, providing more opportunities for genome mining to
discover novel new natural products.
We can now begin to fully exploit combinatorial biosynthesis by either utilizing unnatural starting substrates in
order to alter the final product or mixing and matching gene
clusters with the aim of producing novel structures. A
prime example of the latter is the aforementioned engineering of fluorosalinosporamide from S. tropica. This
fluorinated analog was generated by replacing the fluorination gene flA from Streptomyces cattleya with the salL
chlorinase gene in S. tropica and growing the salL- flA?
mutant strain in the presence of inorganic fluoride [60].
Fluorinated natural products are rare, yet 15 % of all
marketed drugs contain fluorine, demonstrating how useful
genetic engineering can be in incorporating unique and
essential functionalities in molecules.
Furthermore, many genomic studies have revealed that
most of the biosynthetic gene clusters in microorganisms
are cryptic or silent. For example, sequencing Streptomyces
genomes has revealed that each strain has the potential to
produce at least 20 or more secondary metabolites, when
only a fraction of these are produced by conventional fermentation methods [158]. The genetic capability of fungi
has also been underestimated as the model soil fungus
Aspergillus nidulans has 28 putative PKS and 24 NRPS
gene clusters, demonstrating the potential to produce at
least 52 secondary metabolites [223] and in a 2012 review,
the Keller group at Wisconsin extended the analyses to
eight other species of Aspergillus identifying between 33
and 79 putative clusters excluding any terpene synthases,
on the eight chromosomes of this genus [181], thus the
potential is immense.
We now have access to cryptic gene clusters and can
focus on ways to activate them. One method reported by
Tanaka et al. [203], was the addition of rare metals to the
fermentation broth of Streptomyces sloyaensis thus activating the expression of nine genes that were previously
silent or poorly expressed in Streptomyces coelicolor
A3(2). In 2007, Udwary et al. [214] reported the sequence
of S. tropica, identifying 17 potential biosynthetic gene
clusters, including the salinosporamide locus, leading to
studies by Fenical and coworkers eliciting the products of
the products of some of these clusters via specific fermentation conditions, and now that the positions of the
potential producing clusters have been identified, a combination of cloning, expression, and fermentation is being
used to ‘‘unlock’’ these metabolites. Cocultivation with
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Conclusions
Organisms from two of the three domains of life are not
only producers of secondary metabolites with significant
activity as both drugs and leads, but in the last few years,
the investigation of the genomic sequences of such
microbes has shown that we have overlooked most biosynthetic gene clusters by using axenic monoculture conditions. With the development of NGS technologies and the
increasing availability of genetic blueprints, we can now
make informed decisions (e.g., in silico predictions) [133]
about how to characterize and fine tune the expression of
genes, molecular interactions, cross-species gene expression, signal transduction, as well as the activation and
silencing of various genes involved in the production of
bioactive secondary metabolites. Most importantly, we are
now developing the tools needed to uncover unexplored
microbial genes and, correlating with the increasing numbers of genomic sequences available we also expect to see
an increase in the number of new microbial-derived
pharmaceuticals.
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